Caribou Biosciences rises on job cuts, shifts focus to cancer therapies

Shares of Caribou Biosciences CRBU.O rise 3% to 89 cents in extended trading

Co says it is reducing workforce by 32% to extend its cash runway into H2 of 2027; as of March 31, co had about $212.5 mln in cash

CRBU had 147 full-time employees as of March 1 - SEC filing

Co says it will prioritize two cancer therapy programs, CB-010 and CB-011

Also says it is stopping work on lupus and leukemia treatment trials

As of last close, stock down 45% YTD